{"transactions":[{"id":4617514,"issuer":{"id":4101,"kind":"organization","name":"Telix Pharmaceuticals Ltd","symbol":"TLX"},"owners":[{"id":54726,"kind":"person","name":"Smith Darren Charlton","position":1,"cik":"0002122447","reported_name":"Smith Darren Charlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Group Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-09-14T23:20:14.000Z","date":"2026-09-07","kind":"purchase","planned":false,"acquired":true,"shares":2071,"price":9.656,"value":19997.576,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan (\"AU ESPP\"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions  to the AU ESPP from January 1, 2026 - June 30, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Purchase price is recorded in Australian Dollars."}],"balance_after":13992,"source":{"system":"sec-edgar","filing":"0001628280-26-061944","document":"wk-form4_1789428011.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2122447/000162828026061944/wk-form4_1789428011.xml","form_type":"4"}},{"id":823100,"issuer":{"id":4101,"kind":"organization","name":"Telix Pharmaceuticals Ltd","symbol":"TLX"},"owners":[{"id":54726,"kind":"person","name":"Smith Darren Charlton","position":1,"cik":"0002122447","reported_name":"Smith Darren Charlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Group Chief Financial Officer"}}],"security":"Share Rights","published_at":"2026-04-01T23:14:36.000Z","date":"2026-03-29","kind":"exercise","planned":false,"acquired":false,"shares":1111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"expiration_date":"2028-03-31","underlying":"Ordinary Shares","underlying_shares":1111},"source":{"system":"sec-edgar","filing":"0001628280-26-022909","document":"wk-form4_1775085272.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026022909/wk-form4_1775085272.xml","form_type":"4"}},{"id":823099,"issuer":{"id":4101,"kind":"organization","name":"Telix Pharmaceuticals Ltd","symbol":"TLX"},"owners":[{"id":54726,"kind":"person","name":"Smith Darren Charlton","position":1,"cik":"0002122447","reported_name":"Smith Darren Charlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Group Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-04-01T23:14:36.000Z","date":"2026-03-29","kind":"exercise","planned":false,"acquired":true,"shares":1111,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11921,"source":{"system":"sec-edgar","filing":"0001628280-26-022909","document":"wk-form4_1775085272.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026022909/wk-form4_1775085272.xml","form_type":"4"}}]}